Quite recently, based on the data from The Cancer Genome Atlas (TCGA), it was discovered that a variant burden in ABCC1 substantially predicts disease-free survival in breast cancer patients and that this significance was even stronger in cyclophosphamide- and doxorubicin-treated subgroups [26]. Here, ABCC1 is linked to breast carcinoma.